全文获取类型
收费全文 | 510616篇 |
免费 | 33950篇 |
国内免费 | 607篇 |
专业分类
耳鼻咽喉 | 6887篇 |
儿科学 | 16810篇 |
妇产科学 | 13520篇 |
基础医学 | 84515篇 |
口腔科学 | 14453篇 |
临床医学 | 44041篇 |
内科学 | 92823篇 |
皮肤病学 | 12144篇 |
神经病学 | 35928篇 |
特种医学 | 18442篇 |
外国民族医学 | 63篇 |
外科学 | 76821篇 |
综合类 | 8438篇 |
一般理论 | 118篇 |
预防医学 | 38760篇 |
眼科学 | 12089篇 |
药学 | 40411篇 |
中国医学 | 974篇 |
肿瘤学 | 27936篇 |
出版年
2018年 | 4927篇 |
2015年 | 4509篇 |
2014年 | 6063篇 |
2013年 | 9546篇 |
2012年 | 12871篇 |
2011年 | 14271篇 |
2010年 | 8302篇 |
2009年 | 7773篇 |
2008年 | 13697篇 |
2007年 | 14702篇 |
2006年 | 14939篇 |
2005年 | 14357篇 |
2004年 | 14041篇 |
2003年 | 13365篇 |
2002年 | 13237篇 |
2001年 | 24029篇 |
2000年 | 25028篇 |
1999年 | 20453篇 |
1998年 | 5147篇 |
1997年 | 4421篇 |
1996年 | 4759篇 |
1995年 | 4593篇 |
1994年 | 4306篇 |
1993年 | 4123篇 |
1992年 | 15706篇 |
1991年 | 16307篇 |
1990年 | 16418篇 |
1989年 | 15788篇 |
1988年 | 14568篇 |
1987年 | 14412篇 |
1986年 | 13587篇 |
1985年 | 12974篇 |
1984年 | 9612篇 |
1983年 | 8236篇 |
1982年 | 4543篇 |
1981年 | 4215篇 |
1979年 | 9405篇 |
1978年 | 6838篇 |
1977年 | 5754篇 |
1976年 | 5588篇 |
1975年 | 6379篇 |
1974年 | 7630篇 |
1973年 | 7124篇 |
1972年 | 6953篇 |
1971年 | 6680篇 |
1970年 | 6166篇 |
1969年 | 5886篇 |
1968年 | 5557篇 |
1967年 | 5009篇 |
1966年 | 4449篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
Suppression of Rotenone-Treated Human Breast Cancer Stem Cell Survival Using Survivin Inhibitor YM155 is Associated to Oxidative Stress Modulation 下载免费PDF全文
Resda A SyahraniElvira YunitaSeptelia I Wanandi 《Asian Pacific journal of cancer prevention》2020,21(9):2631-2637
Background: Despite recent progress in molecular-targeted therapies, breast cancer remains the primary leading cause of cancer related death among women worldwide. Breast cancer stem cells (BCSCs) are believed to be responsible for therapy resistance and cancer recurrence. We recently demonstrated that human BCSCs (CD24-/CD44+) could survive better than their counterpart non-BCSCs (CD24-/CD44-) when treated with rotenone, possibly due to lower levels of reactive oxygen species (ROS) production, high expression of antioxidant manganese superoxide dismutase (MnSOD), and anti-apoptotic survivin. The aim of this study was to verify the role of survivin on human BCSCs survival under oxidative stress modulation by suppressing its expression using YM155, a survivin inhibitor. Methods: Human BCSCs (ALDH+ cells) were treated with YM155 for 24 h prior to treatment with rotenone for a further 6 h. We determined intracellular superoxide levels were determined using dihydroethidium assay, survivin and MnSOD expression using qRT-PCR, survivin protein level using ELISA, as well as cell viability using trypan blue exclusion and acridine orange/ethidium bromide apoptosis assay. Results: Suppression of survivin expression using YM155 could reduce the survival of rotenone-treated BCSCs, which may be associated with oxidative stress modulation, as shown by increased ROS levels and decreased MnSOD expression. We confirm that survivin is responsible for maintaining BCSCs survival under oxidative stress modulation. Furthermore, YM155 could modulate oxidative stress in BCSCs by reducing MnSOD expression and increasing ROS levels. Conclusion: YM155 treatment could be used to overcome BCSCs resistance to oxidative stress-based anticancer therapies. 相似文献
23.
24.
James I. Geller MD Joseph G. Pressey MD Malcolm A. Smith MD Rachel A. Kudgus PhD Mariana Cajaiba MD Joel M. Reid PhD David Hall PhD Donald A. Barkauskas PhD Stephen D. Voss MD Steve Y. Cho MD Stacey L. Berg MD Jeffrey S. Dome MD PhD Elizabeth Fox MD Brenda J. Weigel MD 《Cancer》2020,126(24):5303-5310
25.
Marco Bandini Sebastiano Nazzani Michele Marchioni Felix Preisser Zhe Tian Marco Moschini Firas Abdollah Nazareno Suardi Markus Graefen Francesco Montorsi Shahrokh F. Shariat Fred Saad Alberto Briganti Pierre I. Karakiewicz 《Clinical genitourinary cancer》2019,17(1):72-78.e4
Background
The rate of noninterventional treatment (NIT) in prostate cancer (PCa) active surveillance (AS) candidates is on the rise. However, contemporary data are unavailable. We described community-based NIT rates within 16 Surveillance Epidemiology and End Results (SEER) registries between 2010 and 2014.Patients and Methods
We identified 23,360 PCa patients who fulfilled the University of California San Francisco AS criteria (prostate-specific antigen [PSA] < 10 ng/mL, clinical T stage ≤ T2a, Gleason score ≤ 6, and positive cores < 33%). Annual NIT rates as well as patient distribution according to PSA, age, number of positive cores, and clinical T stage were studied. Multivariable logistic regression analysis tested NIT predictors.Results
Between 2010 and 2014, the NIT rate increased from 30.2% to 57.5% (P = .004). Within 16 SEER registries, NIT rates ranged from 25.9% to 62%. NIT rate increased uniformly within all examined registries. Of patient and tumor characteristics (PSA > 4 ng/mL, cT2a and > 1 positive core) only the proportion of NIT patients aged < 65 years increased over time from 47.3% to 53.2% (P = .03). By multivariable logistic regression analysis predicting NIT rate, older age (odd ratio [OR] = 1.05), more contemporary year of diagnosis (OR = 1.41), and being unmarried (OR = 1.45) and uninsured (OR = 2.41) were independent predictors.Conclusion
The NIT rate has markedly increased across all examined SEER registries. Nonetheless, important differences distinguish those who received high-end NIT from low-end NIT. PCa characteristics of NIT patients remained unchanged over time. However, in addition to geographical differences in NIT rates, patient characteristics such as age, marital status, and insurance status represent potential NIT access barriers. 相似文献26.
Y. Ermias I.A. Morgan K.M. Curtis M.K. Whiteman L.G. Horton L.B. Zapata 《Contraception》2019,99(5):300-305
ObjectiveIdentify factors associated with healthcare providers' frequency of depot medroxyprogesterone acetate (DMPA) provision to adolescents.Study designWe analyzed data from surveys mailed to a nationally representative sample of public-sector providers and office-based physicians (n=1984). We estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) of factors associated with frequent DMPA provision to adolescents in the past year.ResultsAlthough most providers (>95%) considered DMPA safe for adolescents, fewer reported frequent provision (89% of public-sector providers; 64% of office-based physicians). Among public-sector providers, factors associated with lower odds of frequent provision included working in settings without Title X funding (aOR 0.44, 95% CI 0.30–0.64), reporting primary care as their primary clinical focus versus reproductive or adolescent health (aOR 0.42, 95% CI 0.28–0.61), and providing fewer patients with family planning services. Among office-based physicians, factors associated with lower odds of frequent provision included specializing in obstetrics/gynecology (aOR 0.50, 95% CI 0.27–0.91) and family medicine (aOR 0.21, 95% CI 0.09–0.47) versus adolescent medicine, completing training ≥15 versus <5 years ago (aOR 0.27, 95% CI 0.09–0.83), and reporting that 0–24% of patients pay with Medicaid or other government healthcare assistance versus ≥50% (aOR 0.23, 95% CI 0.09–0.61). The reason most commonly reported by providers for infrequent DMPA provision was patient preference for another method.ConclusionsWhile most providers reported frequently providing DMPA to adolescents, training on evidence-based recommendations for contraception, focused on subgroups of providers with lower odds of frequent DMPA provision, may increase adolescents' access to contraception.ImplicationsAlthough >95% of providers considered depot medroxyprogesterone (DMPA) a safe contraceptive for adolescents, only 89% of public-sector providers and 64% of office-based physicians reported frequently providing DMPA to adolescents. Provider training on evidence-based recommendations for contraception counseling and provision may increase adolescents' access to DMPA and all methods of contraception. 相似文献
27.
Viakhireva I. Musatova E. Bessonova L. Shcherbatyuk Y. Korobkov S. Zhikriveckaya S. Sofronova Ya. Mironova I. Khmelkova D. Konovalov F. Baranova A. Pomerantseva E. Skoblov M. 《Familial cancer》2020,19(3):241-246
Familial Cancer - Despite the acceptance of NextGen sequencing as a diagnostic modality suitable for probands and carriers of Mendelian diseases, its efficiency in identifying causal mutations is... 相似文献
28.
29.
30.